
Quarterly report 2025-Q2
added 01-31-2026
I-Mab EBITDA 2011-2026 | IMAB
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA I-Mab
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 13.8 M | 12.7 M | 9.8 M | 6.7 M | 1.6 M | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.8 M | 1.6 M | 8.92 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | ||
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | ||
|
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | ||
|
ANI Pharmaceuticals
ANIP
|
68.3 M | $ 81.6 | -0.49 % | $ 1.58 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Amgen
AMGN
|
12.8 B | $ 342.65 | -0.08 % | $ 184 B | ||
|
Adagene
ADAG
|
-35.2 M | $ 2.75 | -5.5 % | $ 155 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
Aytu BioScience
AYTU
|
-2.45 M | $ 2.63 | 1.74 % | $ 16.5 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-17.3 M | $ 3.17 | -2.76 % | $ 7.63 B | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
PainReform Ltd.
PRFX
|
-7.2 M | $ 0.68 | -4.45 % | $ 308 K | ||
|
Allena Pharmaceuticals
ALNA
|
-47.3 M | - | 3.16 % | $ 1.9 M | ||
|
AVROBIO
AVRO
|
10.8 M | - | 1083.1 % | $ 745 M | ||
|
Aptose Biosciences
APTO
|
32 K | - | -45.71 % | $ 1.2 M | ||
|
Aravive
ARAV
|
-70 M | - | -13.39 % | $ 1.45 M | ||
|
Biogen
BIIB
|
673 M | $ 178.24 | 1.2 % | $ 26 B | ||
|
Brickell Biotech
BBI
|
-6.32 M | - | -5.38 % | $ 6.06 M | ||
|
Applied Molecular Transport
AMTI
|
-124 M | - | - | $ 10.1 M | ||
|
Beam Therapeutics
BEAM
|
-394 M | $ 27.94 | -4.61 % | $ 2.3 B | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
Ascendis Pharma A/S
ASND
|
-452 M | $ 225.36 | 0.63 % | $ 5 B | ||
|
Athira Pharma
ATHA
|
-99.9 M | - | - | $ 269 M | ||
|
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | ||
|
BioNTech SE
BNTX
|
15.3 B | $ 114.18 | -2.22 % | $ 27.2 B | ||
|
Burford Capital Limited
BUR
|
242 M | $ 9.67 | 0.16 % | $ 1.52 B | ||
|
Arrowhead Pharmaceuticals
ARWR
|
121 M | $ 70.74 | 2.34 % | $ 9.46 B | ||
|
CASI Pharmaceuticals
CASI
|
-41.4 M | $ 0.99 | -0.01 % | $ 135 M | ||
|
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-9.76 M | - | -10.17 % | $ 12.2 K | ||
|
Catalyst Biosciences
CBIO
|
-66.2 M | $ 9.63 | -5.08 % | $ 634 M | ||
|
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-130 M | - | -15.15 % | $ 60.3 M | ||
|
Berkeley Lights
BLI
|
-89 M | - | -7.31 % | $ 87 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-10.1 M | $ 4.05 | -1.22 % | $ 8.81 B | ||
|
Amneal Pharmaceuticals
AMRX
|
312 M | $ 13.65 | -3.3 % | $ 4.22 B | ||
|
AIkido Pharma
AIKI
|
-11.4 M | - | 1.93 % | $ 17.4 M | ||
|
Bellerophon Therapeutics
BLPH
|
-22.4 M | - | -74.18 % | $ 955 K | ||
|
Cerus Corporation
CERS
|
-12.4 M | $ 2.32 | -0.22 % | $ 428 M | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
-24.5 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
-57.6 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
-200 M | - | 4.14 % | $ 49.1 M |